Texas Oncology San Antonio

Clinical research site in San Antonio, Texas · 1214 PINNACLE FLS, SAN ANTONIO, TX 78260-2487 · (865) 603-2246 · Website

Part of US Oncology

As of July 2026, 24 paid clinical trials are recruiting at Texas Oncology San Antonio in San Antonio, Texas. Active studies at this site cover conditions such as Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma and Acinar Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Texas Oncology San Antonio (24)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

for Non-Small Cell Lung Cancer (NSCLC)

40 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361510·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

48 locations incl. Tucson

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

34 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221149·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

71 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for Colon Adenocarcinoma

31 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06997497·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

for Carcinoma, Non-Small-Cell Lung

51 locations incl. Birmingham

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06875310·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

32 locations incl. Birmingham

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

37 locations incl. Birmingham

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

23 locations incl. Phoenix

Sponsor: Immuneering Corporation

Sex: All·Age: 18+

Code: NCT07562152·Phase 3·Recruiting·Listed May 2026

Apply to this trial

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

for Small Cell Lung Cancer (SCLC)

24 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07226999·Phase 2, Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

for Metastatic Colorectal Cancer

6 locations incl. Peoria

Sponsor: EMD Serono Research & Development Institute, Inc.

Sex: All·Age: 18+

Code: NCT07549412·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

for Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

8 locations incl. Torrance

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 1 - 100

Code: NCT05868629·Recruiting·Listed May 2023

Apply to this trial

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

for Limited Stage Small Cell Lung Cancer

32 locations incl. Daphne

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT06773910·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

for Multiple Myeloma

16 locations incl. Tucson

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05972135·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

for Breast Cancer

7 locations incl. Columbia

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05748834·Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

for Cervical Cancer

126 locations incl. Goodyear

Sponsor: GOG Foundation

Sex: Female·Age: 18+

Code: NCT04831580·Recruiting·Listed Apr 2021

Apply to this trial

More research sites in San Antonio

University of Texas Health Science Center at San Antonio (85 trials)
NEXT Oncology (56 trials)
Children's Hospital of San Antonio (32 trials)
Methodist Children's Hospital of South Texas (24 trials)
START San Antonio (22 trials)
The University of Texas Health Science Center at San Antonio (21 trials)
UT Health San Antonio (16 trials)
GSK Investigational Site (13 trials)
Texas Dermatology and Laser Specialists (13 trials)
Texas Oncology - San Antonio (12 trials)

Explore more

Paid clinical trials in San Antonio, TX · Texas clinical trials